cancer-related bowel obstruction
Conditions
Interventions
Octreotide acetate of 300 ug/day is administered primarily as a continuous subcutaneous infusion using a continuous infusion pump. Dosage is fixed at 300 ug/day until Day 4. In patients extubated by
Sponsors
University of Tsukuba
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)In-patients with solid cancer, irrespective of type, who developed bowel obstruction 2)Patients diagnosed with cancer-related bowel obstruction using plain abdominal radiography or computed tomography in addition to symptoms of bowel obstruction such as nausea/vomiting, abdominal pain, and abdominal fullness 3)Patients aged 20 years or over 4)Patients in whom surgery is not indicated 5)Patients providing written informed consent
Exclusion criteria
Exclusion criteria: 1)Patients with cognitive dysfunction 2)Patients with esophageal obstruction 3)Patients with symptomatic brain metastases or meningeal dissemination 4)Patients undergoing anticancer treatment or radiotherapy within the last 2 weeks 5)Patients judged by the physician in charge to be unsuitable for this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Amelioration of abdominal symptoms (subjective parameters) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Reduction in the number of vomiting episodes and the volume of drainage from a gastric tube (Objective parameters) 2) Correlation between subjective and objective parameters 3) Differences in the efficacy of treatment with octreotide acetate among different cancer types or obstruction sites 4) Assessment of safety in octreotide acetate therapy | — |
Countries
Japan
Contacts
Public ContactTakayuki Hisanaga
Tsukuba Medical Center Hospital Division of Palliative care
Outcome results
None listed